20 June 2013
Keywords: antisoma, starts, ph, iii, nsclc, trial, earns
Article | 21 April 2008
Antisoma has started a pivotal Phase III trial of ASA404 combined with first-line chemotherapy in non-small cell lung cancer, triggering ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 April 2008
19 June 2013
© 2013 thepharmaletter.com